Dose-Response and Minimal Duration of Intervention of a New Anti-IL-1R Therapeutic, Rytvela, for Prevention of Preterm Birth and Neonatal Tissue Injury

Sunday, April 24, 2022

11:15 AM – 11:30 AM US MT

Location: Convention Center: Mile High Ballroom 1 CD

CE: Enduring CME: 0.25

Publication Number: 2320.6

Tiffany Habelrih, CHU Sainte-Justine, Montreal, PQ, Canada; David-Étienne Tremblay, Universite de Montreal Faculty of Medicine, Montréal, PQ, Canada; Erica Di Battista, Boston University, Montreal, PQ, Canada; Xin Hou, CHU Ste-Justine, Saint-Laurent, PQ, Canada; Sarah-Eve Loiselle, Universite de Montreal Faculty of Medicine, Montreal, PQ, Canada; France Côté, Université de Montréal, Montréal, PQ, Canada; Christiane Quiniou, Université de Montreal, Montreal, PQ, Canada; Sylvain Chemtob, University of Montreal, Montreal, PQ, Canada

Presenting Author(s)

Tiffany Habelrih, BSc
PhD Student
Université de Montréal
Montreal, Quebec, Canada

Full Presentation

Participants should be aware of the following financial/non-financial relationships:

Tiffany Habelrih, BSc: I do not have any relevant financial / non-financial relationships with any proprietary interests.

David-Étienne Tremblay, Bsc: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Erica Di Battista, High School: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Xin Hou, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Sarah-Eve Loiselle, BSc: I do not have any relevant financial / non-financial relationships with any proprietary interests.

France Côté, BSc: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Christiane Quiniou, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Sylvain Chemtob, MD, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.